Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

Msd R&d Co., Ltd.

Timothy A Cernak

Kun Liu

Andrew William Stamford

Joseph A Kozlowski

Yimin Qian

Yongxin Han

Melissa S Egbertson

Wensheng Yu

Dong-Ming Shen

Hongjun Zhang

Shuwen He

Deping Wang

Yong Zhang

Liangqin Guo

Zhi-Cai Shi

Guoqing Li

Purakkattle J Biju

Derun Li

Subharekha Raghavan

XiaoXia Qian

Abdelghani Achab

Yongqi Deng

Richard Berger

Xavier Fradera

Christopher Joseph Sinz

Qinglin Pu

Shimin Xu

Kevin D Dykstra

Jian Guo

Bart Harper

Alan Whitehead

Meng Yang

Vanessa L Rada

Ming Wang

Jonathan E Wilson

John Qiang Tan

Jonathan A Groeper

Zack Zhiqiang Guo

Xiaoqing Han

Spencer Dreher

Christopher J Sinz

Dong Ming Shen

Lianqin Guo

Zack Zhi Qiang Guo

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof. 

Pyrimidone carboxamide compounds as PDE2 inhibitors

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula I, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I. 

Mineralocorticoid receptor antagonists

Growing community of inventors

Boston, MA, United States of America

Timothy A Cernak